482 related articles for article (PubMed ID: 25733192)
1. 5-Aminosalicylic acid, a specific drug for ulcerative colitis.
Hauso Ø; Martinsen TC; Waldum H
Scand J Gastroenterol; 2015 Aug; 50(8):933-41. PubMed ID: 25733192
[TBL] [Abstract][Full Text] [Related]
2. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine.
Kao J; Kwok K; Das KM
J Clin Gastroenterol; 2010 Sep; 44(8):531-5. PubMed ID: 20495466
[TBL] [Abstract][Full Text] [Related]
3. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
Cohen HD; Das KM
J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699
[TBL] [Abstract][Full Text] [Related]
4. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
[TBL] [Abstract][Full Text] [Related]
5. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
Moum B
Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
[TBL] [Abstract][Full Text] [Related]
6. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
[TBL] [Abstract][Full Text] [Related]
7. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
Marshall JK; Irvine EJ
Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
[TBL] [Abstract][Full Text] [Related]
8. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Sutherland L; Macdonald JK
Cochrane Database Syst Rev; 2006 Apr; (2):CD000543. PubMed ID: 16625536
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.
Jung Y; Kim HH; Kim H; Kong H; Choi B; Yang Y; Kim Y
Eur J Pharm Sci; 2006 May; 28(1-2):26-33. PubMed ID: 16455235
[TBL] [Abstract][Full Text] [Related]
10. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Sutherland L; MacDonald JK
Cochrane Database Syst Rev; 2003; (3):CD000543. PubMed ID: 12917894
[TBL] [Abstract][Full Text] [Related]
11. The role of aminosalicylates in the treatment of ulcerative colitis.
Van Assche G; Baert F; De Reuck M; De Vos M; De Wit O; Hoang P; Louis E; Mana F; Pelckmans P; Rutgeerts P; Van Gossum A; D'Haens G
Acta Gastroenterol Belg; 2002; 65(4):196-9. PubMed ID: 12619425
[TBL] [Abstract][Full Text] [Related]
12. 5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model.
Ikeda I; Tomimoto A; Wada K; Fujisawa T; Fujita K; Yonemitsu K; Nozaki Y; Endo H; Takahashi H; Yoneda M; Inamori M; Kubota K; Saito S; Nagashima Y; Nakagama H; Nakajima A
Clin Cancer Res; 2007 Nov; 13(21):6527-31. PubMed ID: 17975166
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
Prantera C; Kohn A; Campieri M; Caprilli R; Cottone M; Pallone F; Savarino V; Sturniolo GC; Vecchi M; Ardia A; Bellinvia S
Aliment Pharmacol Ther; 2009 Nov; 30(9):908-18. PubMed ID: 19678813
[TBL] [Abstract][Full Text] [Related]
14. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Sandborn WJ
Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
[TBL] [Abstract][Full Text] [Related]
15. Addition of Berberine to 5-Aminosalicylic Acid for Treatment of Dextran Sulfate Sodium-Induced Chronic Colitis in C57BL/6 Mice.
Li YH; Zhang M; Xiao HT; Fu HB; Ho A; Lin CY; Huang Y; Lin G; Bian ZX
PLoS One; 2015; 10(12):e0144101. PubMed ID: 26642326
[TBL] [Abstract][Full Text] [Related]
16. Mesalamine with MMX technology for the treatment of ulcerative colitis.
Schreiber S; Kamm MA; Lichtenstein GR
Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380
[TBL] [Abstract][Full Text] [Related]
17. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
Støa-Birketvedt G; Florholmen J
Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
[TBL] [Abstract][Full Text] [Related]
18. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
Nakajima H; Munakata A; Yoshida Y
J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
[TBL] [Abstract][Full Text] [Related]
19. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine.
Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z
J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547
[TBL] [Abstract][Full Text] [Related]
20. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
